株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の動物用ワクチン市場:動物疾患、技術、動物、地域別 - 動向および予測

Global Veterinary Vaccines Market Segmented by Animal diseases , by Technology, by Animal Type & by Geography - Trends and Forecast (2017 - 2022)

発行 Mordor Intelligence LLP 商品コード 319396
出版日 ページ情報 英文 190 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
世界の動物用ワクチン市場:動物疾患、技術、動物、地域別 - 動向および予測 Global Veterinary Vaccines Market Segmented by Animal diseases , by Technology, by Animal Type & by Geography - Trends and Forecast (2017 - 2022)
出版日: 2017年01月24日 ページ情報: 英文 190 Pages
概要

世界の動物用ワクチン市場は2014年に120億米ドルとなる見込みです。同市場は今後もCAGR8.8%で拡大し、2019年には190億米ドルに達するとみられています。家畜やコンパニオンアニマルの増加、動物の慢性疾患の発症率上昇などが、より良い動物医療のニーズを促進しています。

当レポートでは、世界の動物用ワクチン市場の動向と将来予測、市場に参入する主要企業の競合環境、市場シェア、近年の動向とともにプロファイルをまとめています。

第1章 イントロダクション

第2章 市場分析

  • 動物医療製品市場
  • 動物医療とヒトの医療

第3章 市場動向

  • 市場促進因子
    • ペット所有率の上昇
    • 栄養の改善
    • 食品安全に対する消費者の意識向上
    • 家畜生産の増大
    • 人畜共通感染症、食品媒介疾患
  • 市場阻害因子
    • 耕作地と水の不足
    • 耕地に関する競争激化
    • 費用対効果の高い生産
  • ポーターズファイブフォース分析

第4章 世界の動物用ワクチン市場セグメンテーション:動物別、疾患別

  • コンパニオンアニマル
  • 鶏ワクチン市場:疾患別
  • 豚ワクチン市場:疾患別
  • 馬ワクチン市場:疾患別
  • 世界の動物用ワクチン市場:技術別
    • トキソイドワクチン
    • 組換えワクチン
    • 不活化ワクチン
    • 弱毒化生ワクチン
  • 世界の動物用ワクチン市場:地域別
    • 北米
    • 欧州
    • アジア太平洋地域

第5章 競合環境

  • 市場における主要参入企業
  • 合併・買収
  • 新製品上市
  • 協定、連携、提携

第6章 企業プロファイル

  • Zoetis animal healthcare
  • Merck
  • Merial (Animal Health Division Of Sanofi)
  • Elanco
  • Bayer healthcare
  • Novartis Animal Health, Inc.
  • Virbac
  • Boehringer Ingelheim

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Description

The global market for veterinary vaccines has been estimated at USD 11,083 million in 2014 and is projected to reach USD 19,021 million by 2020 at a CAGR of 9.42% during the forecast period from 2014 to 2021.

Global Veterinary Vaccines Market- Market Dynamics

Veterinary vaccines help to improve health and welfare of animals, increase production of livestock in a cost-effective manner and prevent transmission of diseases among animals and also to humans. Efficient animal production and better access to high-quality protein dramatically increase meat and egg production and contribute to greater economic outcome. Also, the rapid development of animal vaccines can play an effective role in controlling emerging diseases. Veterinary vaccines comprise only approximately 23% of the global market for animal health products.

Drivers

There are several factors listed in the study that drive the growth of the global veterinary vaccines market. Some of them are:

Technological innovations

Growing awareness of animal health

Increasing investments by government bodies and associations

Increased demand for animal protein, including milk, meat, eggs, and fish

Increased expenditure on health care of companion animals

Restraints

Some of the factors restraining the market growth are:

Rising maintenance costs for storage of vaccines

Increasing adoption of vegetarian food in major economies owing to increasing risk of obesity and other chronic disorders

Persistent economic slowdown

The veterinary vaccines market is segmented on the basis of products, diseases, technologies, and regions. Based on product type, the market is categorized into companion animal vaccines, livestock vaccines, poultry vaccines, porcine vaccines, equine vaccines, aquaculture vaccines and other animal vaccines. The porcine vaccine is the largest sub-segment contributing to a major share of the market, whereas companion animal vaccines are the fastest growing segment due to the increasing prevalence of zoonotic diseases in humans and growing pet population. The technology segment includes live attenuated, inactivated, subunit, conjugate, toxoid, recombinant and DNA vaccines. Live attenuated vaccine technology is the major technology in the veterinary vaccines market. The disease type segment includes Rabies, Brucellosis, Leptospirosis, Influenza, Rift Valley fever, Newcastle disease, Nipah virus infection, Hendra virus infection, Porcine Reproductive and Respiratory Syndrome virus and Japanese encephalitis Q fever.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). The European region is the leading veterinary vaccine market, closely followed by the United States. Middle East, Brazil, Argentina, Mexico, Turkey, China, and India are lucrative markets for veterinary vaccines, owing to the growing demand for livestock, development of new products and favorable government initiatives.

The top 3 players in the veterinary vaccines market are Pfizer, Merck, and Sanofi-Aventis, based on the revenues they generate each year. Pfizer is the market leader in the veterinary vaccines market (by revenue) but Merck is the market leader in livestock vaccines market and Sanofi-Aventis is leading in the companion vaccines market. There have been a few mergers/acquisitions by the key players in the veterinary vaccines market to expand their product portfolio in order to top the global market. Ex: Pfizer acquiring Wyeth, which supposedly is the largest acquisition. The industry players have adopted certain growth strategies to excel in the veterinary vaccines market.

Some of the key players in the market are:

Bayer Healthcare

Boehringer Ingelheim

Ceva Animal Health, Inc.

Elanco

Merck

Merial (Animal Health Division of Sanofi)

Key Deliverables in the Study

Market analysis for the veterinary vaccines market, with region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the veterinary vaccines market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.

Table of Contents

1. INTRODUCTION

  • 1.1 Market Definition
  • 1.2 Market Recent Trends

2. Market Analysis

  • 2.1 Market Animal Health Products
  • 2.2 Animal medicines vs. human Medicines

3. Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Increase in pet ownership
    • 3.1.2 Improved Nutrition
    • 3.1.3 Intensifying consumer focus on food safety
    • 3.1.4 Greater Livestock production
    • 3.1.5 Increasing Zoonotic and Foodborne Diseases
  • 3.2 Market Constraints
    • 3.2.1 Scarcity of arable land and water
    • 3.2.2 Increased competition for cultivated land
    • 3.2.3 Cost-effective production
  • 3.3 Porter's Five Force Analysis
    • 3.3.1 Threat of New Entrant
    • 3.3.2 Internal Rivalry
    • 3.3.3 Buyer bargaining power
    • 3.3.4 Supplier bargaining power
    • 3.3.5 Threat of substitutes

4. Global veterinary vaccine market Segmentation, By Type of Animals, based on diseases

  • 4.1 Companion Animals
    • 4.1.1. 1 Disease mainly transferred by Saliva through Bites and Scratch
    • 4.1.1. 1.1 Capnocytophaga canimorsus
    • 4.1.1. 1.2 Pasteurella multocida
    • 4.1.1. 1.3 Cat scratch disease
    • 4.1.1. 1.4 Rabies
      • 4.1.1.2 Enteric diseases with mainly fecal-oral transmittance
      • 4.1.1.2.1 Salmonellosis
      • 4.1.1.2.2 Campylobacteriosis
      • 4.1.1.2.3 Toxocarosis
      • 4.1.1.2.4 Protozoans
      • 4.1.1.3 Respiratory Tract Diseases
      • 4.1.1.3.1 BRSV
      • 4.1.1.3.2 Enzootic Bronchopneu
      • 4.1.1.3.3 EVPC
      • 4.1.1.3.4 IBR
      • 4.1.1.4 Gastrointestinal Diseases
      • 4.1.1.4.1 BVD/MD
      • 4.1.1.4.2 Leptospirosis
  • 4.2 Poultry Vaccines market, by diseases
    • 4.2.1 Bronchitis
    • 4.2.2 Avian Influenza
    • 4.2.3 Marek's Disease
    • 4.2.4 Newcastle Disease
  • 4.3 Pig vaccines market, by disease
    • 4.3.1 Porcine reproductive disease
    • 4.3.2 Swine Influenza
    • 4.3.3 Swine Pneumonia
  • 4.4 Equine Vaccines market, By Disease
    • 4.4.1 Encephalomyelitis
    • 4.4.2 Rhinopneumonitis
    • 4.4.3 Influenza (Horse Flu)
  • 4.5 Global Veterinary Vaccines Market, By Technology
    • 4.5.1 Toxoid Vaccines
    • 4.5.2 Recombinant Vaccines
    • 4.5.3 Inactivated Vaccines
    • 4.5.4 Live Attenuated Vaccines (LAV)
  • 4.6 Global veterinary vaccines market Segmentation, By Geography
    • 4.6.1 North America
      • 4.6.1.1 US
      • 4.6.1.2 Mexico
      • 4.6.1.3 Canada
    • 4.6.2 Europe
      • 4.6.2.1 France
      • 4.6.2.2 Italy
      • 4.6.2.3 Germany
      • 4.6.2.4 Spain
      • 4.6.2.5 Sweden
      • 4.6.2.6 Rest of Europe
    • 4.6.3 Asia-Pacific
      • 4.6.3.1 India
      • 4.6.3.2 China
      • 4.6.3.3 Japan
      • 4.6.3.4 Rest of Asia-Pacific

5. Competitive landscape

  • 5.1 Major players in the market
  • 5.2 Mergers and acquisitions
  • 5.3 New product launches
  • 5.4 Agreement, Collaborations, and Partnerships
  • 5.5 Recommendations for New players in the market
  • 5.6 Recommendation for Existing players in the market
  • 5.7 Market Share Analysis

6. Company profiles

  • 6.1 Zoetis Animal Healthcare
    • 6.1.1 Financial Overview
    • 6.1.2 Business overview
    • 6.1.3 Business strategies
  • 6.2 Merck
    • 6.2.1 Financial Overview
    • 6.2.2 Business overview
    • 6.2.3 Business strategies

6. 3 Merial (Animal Health Division of Sanofi)

    • 6.3.1 Financial Overview
    • 6.3.2 Business overview
    • 6.3.3 Business strategies
  • 6.4 Elanco
    • 6.4.1 Financial Overview
    • 6.4.2 Business overview
    • 6.4.3 Business strategies
  • 6.5 Bayer healthcare
    • 6.5.1 Financial Overview
    • 6.5.2 Business overview
    • 6.5.3 Business strategies
  • 6.6 Ceva Animal Health, Inc.
    • 6.6.1 Financial Overview
    • 6.6.2 Business overview
    • 6.6.3 Business strategies
  • 6.7 Virbac
    • 6.7.1 Financial Overview
    • 6.7.2 Business overview
    • 6.7.3 Business strategies
  • 6.8 Boehringer Ingelheim
    • 6.8.1 Financial Overview
    • 6.8.2 Business overview
    • 6.8.3 Business strategies

7. Appendix

  • 7.1. Abbreviations
  • 7.2. Sources
  • 7.3. Bibliography
  • 7.4. Disclaimer
Back to Top